NASDAQ: BLTE - Belite Bio, Inc

半年間の収益性: +38.29%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール Belite Bio, Inc

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について Belite Bio, Inc

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients.

さらに詳しく
The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

IPO date 2022-04-29
ISIN US07782B1044
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://belitebio.com
Цена ао 69.49
1日あたりの価格変動: -2.94% (69.485)
週ごとの価格変動: +6.73% (63.19)
月ごとの料金変更: +22.9% (54.88)
3ヶ月間の価格変動: +8.19% (62.34)
半年間の価格変動: +38.29% (48.7702)
年間の価格変動: +77.96% (37.9)
年初からの価格変動: +6.31% (63.44)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 0 0
P/BV 13.5 1
P/E 0 0
EV/EBITDA -36.24 0
合計: 1.13

効率

名前 意味 学年
ROA, % -33.42 0
ROE, % -34.98 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.0283 10
合計: 9

成長の衝動

名前 意味 学年
収益性 Revenue, % 0 0
収益性 Ebitda, % 453.14 10
収益性 EPS, % 398.1 10
合計: 8
さらに詳しく

機関 音量 共有, %
Armistice Capital, LLC 36000 0.12
Morgan Stanley 22421 0.08
State Street Corporation 17557 0.06
Cubist Systematic Strategies, LLC 16882 0.06
Marshall Wace LLP 16011 0.05
JP Morgan Chase & Company 14267 0.05
Point72 Asset Management, L.P. 7700 0.03
Geode Capital Management, LLC 6700 0.02
Jump Financial, LLC 5200 0.02
Renaissance Technologies, LLC 4900 0.02

ETF共有, %年間の利益率, %配当金, %
Virtus LifeSci Biotech Clinical Trials ETF 0.76712 63.04 0.33
SPDR S&P Emerging Markets Small Cap ETF 0.03878 5.46 3.03583
SPDR S&P China ETF 0.02029 17.02 3.40103
SPDR Portfolio Emerging Markets ETF 0.00475 11.59 3.1879
0.2124.282.49



スーパーバイザー 役職 支払い 生年
Dr. Yu-Hsin Lin M.B.A., Ph.D. Chairman of the Board of Directors & CEO N/A 1979 (46 年)
Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. CFO & Director N/A 1985 (40 年)
Dr. Nathan L. Mata Ph.D. Chief Scientific Officer N/A 1967 (58 年)
Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. Chief Medical Officer & Member of Ophthalmology Clinical Advisory Board

住所: United States, San Diego. CA, 12750 High Bluff Drive - Googleマップで開く, Yandexマップを開く
Webサイト: https://belitebio.com